Logo image of HEVI.CA

HELIUM EVOLUTION INC (HEVI.CA) Stock Fundamental Analysis

TSX-V:HEVI - TSX Venture Exchange - CA42328K1021 - Common Stock - Currency: CAD

0.175  0 (0%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to HEVI. HEVI was compared to 32 industry peers in the Chemicals industry. The financial health of HEVI is average, but there are quite some concerns on its profitability. HEVI is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

HEVI had negative earnings in the past year.
In the past year HEVI has reported a negative cash flow from operations.
HEVI.CA Yearly Net Income VS EBIT VS OCF VS FCFHEVI.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 -2M -4M -6M

1.2 Ratios

HEVI's Return On Assets of -22.16% is on the low side compared to the rest of the industry. HEVI is outperformed by 65.63% of its industry peers.
HEVI's Return On Equity of -23.16% is in line compared to the rest of the industry. HEVI outperforms 40.63% of its industry peers.
Industry RankSector Rank
ROA -22.16%
ROE -23.16%
ROIC N/A
ROA(3y)-30.75%
ROA(5y)N/A
ROE(3y)-69.75%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
HEVI.CA Yearly ROA, ROE, ROICHEVI.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 -20 -40 -60 -80 -100

1.3 Margins

HEVI does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
HEVI.CA Yearly Profit, Operating, Gross MarginsHEVI.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023

More info and screens

6

2. Health

2.1 Basic Checks

HEVI has about the same amout of shares outstanding than it did 1 year ago.
HEVI has a worse debt/assets ratio than last year.
HEVI.CA Yearly Shares OutstandingHEVI.CA Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 20M 40M 60M 80M
HEVI.CA Yearly Total Debt VS Total AssetsHEVI.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2M 4M 6M 8M 10M

2.2 Solvency

HEVI has an Altman-Z score of 19.72. This indicates that HEVI is financially healthy and has little risk of bankruptcy at the moment.
HEVI has a better Altman-Z score (19.72) than 93.75% of its industry peers.
A Debt/Equity ratio of 0.00 indicates that HEVI is not too dependend on debt financing.
With an excellent Debt to Equity ratio value of 0.00, HEVI belongs to the best of the industry, outperforming 93.75% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 19.72
ROIC/WACCN/A
WACCN/A
HEVI.CA Yearly LT Debt VS Equity VS FCFHEVI.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 0 5M -5M 10M

2.3 Liquidity

A Current Ratio of 14.35 indicates that HEVI has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 14.35, HEVI belongs to the top of the industry, outperforming 96.88% of the companies in the same industry.
HEVI has a Quick Ratio of 14.35. This indicates that HEVI is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 14.35, HEVI belongs to the top of the industry, outperforming 96.88% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 14.35
Quick Ratio 14.35
HEVI.CA Yearly Current Assets VS Current LiabilitesHEVI.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2M 4M 6M 8M 10M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for HEVI have decreased strongly by -36.07% in the last year.
EPS 1Y (TTM)-36.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%69.35%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
HEVI.CA Yearly Revenue VS EstimatesHEVI.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023
HEVI.CA Yearly EPS VS EstimatesHEVI.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for HEVI. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
HEVI.CA Price Earnings VS Forward Price EarningsHEVI.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
HEVI.CA Per share dataHEVI.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.02 -0.02 0.04 0.06 0.08 0.1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

HEVI does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

HELIUM EVOLUTION INC

TSX-V:HEVI (3/7/2025, 7:00:00 PM)

0.175

0 (0%)

Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryChemicals
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners6.28%
Inst Owner ChangeN/A
Ins Owners17.26%
Ins Owner ChangeN/A
Market Cap16.81M
Analysts84
Price Target0.36 (105.71%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.62
P/tB 1.62
EV/EBITDA N/A
EPS(TTM)-0.02
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.03
FCFYN/A
OCF(TTM)-0.01
OCFYN/A
SpS0
BVpS0.11
TBVpS0.11
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -22.16%
ROE -23.16%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-30.75%
ROA(5y)N/A
ROE(3y)-69.75%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 7939.13%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 14.35
Quick Ratio 14.35
Altman-Z 19.72
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)8129.61%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-36.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%69.35%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-18.93%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y57.28%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y76.02%
OCF growth 3YN/A
OCF growth 5YN/A